Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05661201 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jan 2026 to Jan 2027v8
  2. Eligibility criteria expanded, about 28 words Study arms: 4 to 5v7 Show 1 more changeShow less
    • Study arms: 4 to 5

    See this version in full on ClinicalTrials.gov ↗

  3. Site contact updatedv6
  4. Study arms: 1 to 4v5
  5. Start date changed from estimate of Apr 2023 to Apr 12, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Feb 2023 to Apr 2023v3
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Jan 2023 to Feb 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Jan 2023 to Feb 2023
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.
Trial Details
NCT Number NCT05661201
Lead Sponsor Georgetown University
Collaborators: Immune System Key Ltd
Conditions Solid Tumor, KRAS Mutation-Related Tumors
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov